Supplementary

Factors	Score
Age (years)	
18–39	0
40–59	30
≥60	49
Race	
White	5
Black	25
Others	0
Cohabitation status	
Non-cohabitation	12
Cohabitation	0
Income	
Low	19
High	0
Tumor size (cm)	
(0–2]	0
(2–5]	6
>5	20
Lymph node status	
No	0
Yes	14
Tumor grade	
Well/moderately differentiated	0
Poorly/un-differentiated	31
Histotype	
IDC	0
ILC	19
Others	16
Molecular subtype	
$HR^{+}/HER2^{+}$	0
$HR^{-}/HER2^{+}$	14
HR⁺/HER2 [−]	23
TN	100

Table S1	(continued)
----------	-------------

Table S1 (continued)	
Factors	Score
Brain metastasis	
Yes	80
No	0
Liver metastasis	
Yes	39
No	0
Lung metastasis	
Yes	18
No	0
Chemotherapy	
No/unknown	36
Yes	0

IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; HR, hormone receptor; HER2, human epidermal growth factor receptor-2; TN, triple-negative (HR⁻HER2⁻).




Figure S1 Calibration curves for the 3- and 5-year BCSS of the non-surgery group. (A) Internal validation for the 3-year BCSS of the non-surgery group. (B) Internal validation for the 5-year BCSS of the non-surgery group. (C) External validation for the 3-year BCSS of the non-surgery group. (D) External validation for the 5-year BCSS of the non-surgery group. BCSS, breast cancer-specific survival.